EUCTR2007-003407-12-GR进行中（未招募）不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by an Open Label Extension Phase in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient is male or female, aged 18 to 80 years old.
- •2.Patient weighs = 40 kg (88 lb).
- •3.Written informed consent has been obtained.
- •4.Written Data Protection Consent (European sites only) has been obtained.
- •5.Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable.
- •6.Patient has urinary incontinence as a result of neurogenic detrusor overactivity for a period of at least 3 months prior to screening as a result of spinal cord injury, determined by documented patient history. In addition patients must have a stable neurological injury level at T1 or below (cervical injuries are excluded) occurring = 6 months prior to screening.
- •7.Patient has detrusor overactivity (defined as a phasic rise in bladder pressure during the filling phase determined by urodynamics) demonstrated during the screening period or Day 1 (prior to randomization).
- •8.Patient is able to complete study requirements including bladder diary completion and attend all study visits, in the opinion of the investigator.
- •9.Patient has not been adequately managed with one or more anticholinergics for their urinary incontinence, in the opinion of the investigator. Not adequately managed is defined as an inadequate response or intolerable side effects after at least one month of anticholinergic therapy on an optimized dose.
- •10.For patients taking anticholinergic medication for their neurogenic overactive bladder, dose is stable and patient is willing to maintain same dosing during study participation.
- •11.Patient has a negative pregnancy result if female and of childbearing potential.
- •The following criteria are also required for entry into the study at Randomization/Day 1:
- •12.Patient experiences > 14 episodes of urinary incontinence per week determined by completion of patient bladder diary (7 consecutive days) during the screening period with:
- •A minimum of 5 days of diary completion within the 7 day diary completion period
- •No more than 2 incontinent-free days within the 7 day diary completion period
- •13.Patient currently uses, or is willing to use, clean intermittent catheterization (CIC) to empty the bladder (indwelling catheter is not permitted). Patients currently on CIC should be willing to maintain an established CIC frequency throughout the study. Caregiver may perform CIC.
- •14.Patients with a negative urine culture result must take an antibiotic medication for 3 days immediately prior to Randomization/Day 1 and agree to continue antibiotic medication for at least 3 days following treatment. Patients with a positive urine culture result indicating urinary tract infection (UTI) must take an antibiotic to which the identified organism is sensitive for at least 5 days immediately prior to Randomization/Day 1 and continue for 3 days following the procedure (or longer as needed) and patient is asymptomatic for UTI on day of treatment. A UTI is defined as either a positive urine culture result with a bacteriuria count of > 105 CFU/mL conjoint with a leukocyturia > 5/hpf at screening or a positive urine culture that, in the investigator’s opinion, requires antibiotic therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient has history or evidence of any pelvic or urological abnormalities including but not limited to the following:
- •elevated serum creatinine > 2 times the upper limit of normal (reference range)
- •history of or current hematuria, 1) if the hematuria is determined to be a pathologic condition or 2) is uninvestigated
- •interstitial cystitis in the opinion of the investigator
- •bladder stones within 6 months of screening
- •surgery or bladder disease other than detrusor overactivity that may impact bladder function with the exception of surgeries for bladder stones (> 6 months) and stress incontinence, uterine prolapse, rectocele, or cystocele (>1 year) from screening
- •2.Patient has had previous or current botulinum toxin therapy of any serotype for any urological condition or, treatment within 3 months of Randomization/Day 1 for any other condition or use.
- •3.Patient has been immunized for any botulinum toxin serotype.
- •4.Patient discontinued anticholinergic medication for overactive bladder < 21 days prior to Randomization/Day 1.
- •5.Patient has a history or current diagnosis of bladder cancer or has urine cytology results which may indicate bladder cancer not ruled out by investigator at Randomization/Day 1. Suspicious urine cytology abnormalities require the investigator’s assessment to ensure that the findings are not indicative of malignancy.
- •6.Patient is male with previous or current diagnosis of prostate cancer or a PSA > 10 ng/L. Patients with a PSA > 4 ng/L but < 10 ng/L must have prostate cancer ruled out to the satisfaction of the investigator according to local site practice.
- •7.Patient has a detrusor compliance below 20 mL/cm H2O by urodynamic evaluation performed during the screening period through Day 1 (prior to randomization).
- •8.Patient has 24 hour total volume voided > 3000 mL of urine determined by completion of patient bladder diary collected over one consecutive 24 hour period during the 7 day diary collection period prior to Randomization/Day1.
- •9.For patients who micturate or have a mixed catheterization/spontaneous micturition pattern, patient has a post void residual volume above 150 mL.
- •10.Patient has an active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening.
- •11.Patient uses any anti-platelet or anticoagulant therapy or is using medications with anticoagulative effects within 3 days prior to treatment. Some medications may need to be withheld for > 3 days per clinical judgment of the investigator (refer to Section 8.2.2 Prohibited Medications/Treatments for details).
- •12.Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diatheses.
- •13.Patient has had concurrent treatment or treatment within 6 months of Randomization/Day 1 with capsaicin or resiniferatoxin.
- •14.Patient is currently using or plans to use an implanted or non-implantable electrostimulation/neuromodulation device for treatment of overactive bladder.
- •15.Patient has a known allergy or sensitivity to any components of the study medication, anesthetics or antibiotics or any other products associated with the treatment and general study procedures.
- •16.Patient has any medical condition that may put the patient at increased risk with exposure to BOTOX® including diagnosed myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis.
- •17.Patient is female and pregnant, nursing or planning a pregnancy during the study, or of ch
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2018-002303-33-BECB Biopharma SR625
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancernon-spread Castration-Resistant Prostate Cancer10036958NL-OMON54510Aragon Pharmaceuticals, Inc.35
进行中（未招募）
1 期
A study to look at the effect and how safe drug VIS649 is in patients with kidney diseaseEUCTR2019-002531-29-GBVisterra, Inc.144
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin, Alone.Type 2 Diabetes MellitusEUCTR2009-010224-25-HUBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
Research study testing the safety and tolerability of the investigationaldrug, BMS-708163, compared to placebo (inactive substance) in subjectswith prodromal Alzheimer's DiseaseALZHEIMER DISEASEMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2009-010067-16-SEBristol-Myers Squibb International Corporation540